CDK9 Inhibitor Crystalline Forms Stability Processability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for improved forms of a compound that acts as a CDK9 modulator, specifically with enhanced stability and processability, as well as improved processes for preparing these compounds, to effectively target CDK9 for cancer therapy.
Innovation Solution
The development of novel crystalline forms of the compound, including Forms I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, and XIII, which can be crystallized with or without coformers, offering improved stability and processability, and methods for their preparation, including co-crystallization and slurry processes, to facilitate pharmaceutical formulations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If the compound is used in amorphous form, then it can be prepared relatively easily, but it exhibits poor stability and poor processability
Solution Approach 1:
The patent transforms the compound from amorphous to crystalline state, changing its physical form and molecular arrangement. This parameter change results in improved stability and processability while maintaining the compound's chemical identity and CDK9 modulator activity
Solution Approach 2:
The patent creates co-crystalline forms by combining the compound with coformers (such as organic acids or bases) to form stable crystalline complexes. These composite crystalline structures enhance both stability and processability compared to the amorphous form
2Stability of the object's composition
If novel crystalline forms are developed, then stability and processability are improved, but the complexity of preparation processes increases
Solution Approach 1:
The patent employs preliminary actions such as selecting appropriate solvents, temperatures, and pH conditions before crystallization to facilitate the formation of desired crystalline forms. These pre-planned conditions simplify the overall process despite the complexity of obtaining specific crystal structures
Solution Approach 2:
The patent uses coformers as intermediaries to mediate between the compound and the crystallization process. These coformers facilitate the formation of stable crystalline structures and can simplify the preparation process by acting as templates or stabilizing agents during crystallization
3Reliability
If co-crystallization with coformers is performed, then stability and processability are enhanced, but the number of steps in the preparation process increases
Solution Approach 1:
The patent merges the crystallization step with the formulation step by incorporating coformers during the crystallization process itself. This combining of operations creates reliable crystalline forms with improved properties while minimizing the total number of separate process steps
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These crystalline forms provide enhanced stability and processability, enabling their use in pharmaceutical formulations and effective modulation of CDK9 activity, thereby potentially improving cancer treatment outcomes by inhibiting aberrant CDK activity and inducing apoptosis in cancer cells.
Implementation Method 1
The present disclosure provides novel crystalline forms of a compound of Formula I, as provided herein, processes for preparing the crystalline forms of the compound, and optionally isolating such crystalline forms
Data Source
AI summary
The present disclosure provides novel crystalline forms of a compound that acts as a CDK9 modulator, processes for preparing the novel crystalline forms of a compound that acts as a CDK9 modulator, and uses thereof.